Blood pressure targets in patients with chronic kidney disease:Comments and controversies  

作　　者：Ying Zheng Guangyan Cai Xiangmei Chen 

机构地区：[1]Department of Nephrology,First Medical Center of Chinese PLA General Hospital,National Key Laboratory of Kidney Diseases,National Clinical Research Center for Kidney Diseases,Beijing Key Laboratory of Kidney Disease Research,Beijing 100853,China

出　　处：《Chinese Medical Journal》2024年第3期270-272,共3页中华医学杂志（英文版）

基　　金：supported by grants from the Beijing Science and Technology Project(No.Z221100007422121);Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine(No.ZYYCXTD-C-202005);National Natural Science Foundation of China(Nos.32141005,82030025,81830019,and 82170686);Clinical Research Support Fund,Young Talent Project,Chinese PLA General Hospital(Nos.2019XXMBD-005,2019XXJSYX01)

摘　　要：According to the Global Burden of Disease Study 2017,there are 132 million patients with chronic kidney disease(CKD)in China,^([1])and the prevalence of hypertension in Chinese patients with CKD(67.3%)is significantly higher than that in the general population(23.2%).^([2,3])CKD is both a cause and a consequence of hypertension,and these two conditions form a vicious cycle that leads to the high prevalence rate of hypertension in patients with CKD.Uncontrolled hypertension accelerates the deterioration of renal function,which significantly increases the risk of developing end-stage renal disease(ESRD),as well as cardiovascular and cerebrovascular diseases,leading to poor patient outcomes.

关 键 词：PATIENTS Blood HYPERTENSION 

分 类 号：R692[医药卫生—泌尿科学]